Lutris Pharma Announces Positive Updated Phase 2 Data Demonstrating Durable, Mechanism-Directed Benefit of LUT014 Gel for EGFRI-Induced Acneiform Rash at the EADV Congress
TEL AVIV, Israel, Oct. 1, 2026, 07:03 GMT-04
Lutris-Pharma
Read full article →